Abcuro secures $66m to support clinical trial of ulviprubart for IBM
Abcuro expects top line results in the second half of 2028.
Clinical Trials
Enrolment concludes in Lynch’s Phase II rhPDGF-BB study
United Therapeutics completes enrolment for TETON-PPF trial
Leal Therapeutics raises $30m to fund schizophrenia and ALS trials
Fate Therapeutics begins Phase II trial of FT819 for lupus nephritis
FDA approves ArkBio’s ziresovir for Phase II trial in severe RSV
FDA grants clearance for PhenoNet Phase III trial in early Alzheimer’s
SCRI and MSD to broaden US oncology trial access
